Search Results

Your search for Richard M. Stone, MD matches 2 pages

Showing 1 - 2

By Richard M. Stone, MD / 2014 ASH Annual Meeting

Richard M. Stone, MD, on the SWOG S1117 Study

Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract LBA-5, “A Randomized Phase II Study of Azacitidine Combined With Lenalidomide or With Vorinostat vs Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North...

leukemia

myelodysplastic syndromes

By James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD / 2014 ASH Annual Meeting

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinical trials: different doses of daunorubicin for AML; comparing azacitidine plus lenolidomide to vorinostat vs azacitidine monotherapy in...

Apr

Today In Oncology

Search Results

Your search for Richard M. Stone, MD matches 2 pages

Richard M. Stone, MD, on the SWOG S1117 Study

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

Financial Hardships Caused by Cancer Are Long-Lasting for Many Working-Age Adults

MRI-Guided Duration of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Immunotherapy Plus FOLFIRI for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

AUA ASCO and SUO Publish 2024 Amendment to Nonmetastatic Muscle Invasive Bladder Cancer Guidelines

Barriers to Autologous Hematopoietic Cell Transplantation in Multiple Myeloma